Receive The Newest Study Notifications

Active U.S. Investigational New Drug (IND) status extends Phase 2b clinical study in moderate to severe Ulcerative Colitis (UC) clinical trial to U.S. patients ABX464 Phase 2b UC trial is already ongoing in 15 European countries and Canada Enrollment of first U.S....

Mayzent® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe1 Mayzent addresses an unmet need for SPMS patients with active disease who, until now, did...

LONDON, Jan 20, 2020 (GLOBE NEWSWIRE via COMTEX) -- LONDON, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ("Chi-Med") (aim/nasdaq:HCM) today announces that the independent Data Monitoring Committee ("IDMC") of the Phase III pivotal study of...

Fasenra being evaluated in eight eosinophil-driven diseases beyond severe asthma AstraZeneca today announced three new trials for Fasenra (benralizumab) in skin diseases, adding to five trials already underway for the medicine in eosinophil-driven diseases (EDDs)...

Surge of Research Organizations Investing in Florence Shows New Wave of Site Leadership in Streamlining Study Operations ATLANTA - January 16, 2020 - (Newswire.com) Florence, an Atlanta-based clinical trial software company, today announces that it doubled the number...

WAKEFIELD, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage pharmaceutical company, is pleased to inform shareholders that the Company has dosed the first cohort in its Phase 1 trial to investigate the...

Kala Pharmaceuticals has completed enrollment in the STRIDE 3 trial for KPI-121 0.25%, a treatment for temporary dry eye relief, according to a press release. The enrollment follows a previous new drug application rejection from the FDA, which said that efficacy data...

OXFORD, UK / ACCESSWIRE / January 17, 2020 / IntraBio Inc, a late-stage biopharmaceutical company, is pleased to share that it has completed enrollment for its IB1001-201 Clinical Trial. IB1001-201 investigates N-Acetyl-L-Leucine (IB1001) for both the symptomatic, and...

The House Energy and Commerce Subcommittee on Health held a hearing on cannabis with much of the focus on research, with the Drug Enforcement Administration revealing that it has a cultivation licensing proposal pending before the White House Office of Management and...

CAMBRIDGE, Mass., Jan. 16, 2020 /PRNewswire/ -- Neuroptika, a privately held biotechnology company focused on the development of novel regenerative treatments for ophthalmic diseases, today announced that the first patient was enrolled in a Phase 2 clinical trial of...

CHAPPAQUA, N.Y., Jan. 16, 2020 /PRNewswire/ -- BioTheryX, Inc., a clinical stage biotechnology company creating new classes of compounds based on multi-kinase inhibition and targeted protein degradation, today announced the initiation of patient dosing in its first...

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the publication of a new randomized controlled trial (RCT) which demonstrated that the use of PICO Single Use Negative Pressure Wound Therapy System (sNPWT) significantly...

Novotech CRO the largest biotech CRO in the Asia-Pacific said the region has had a record year for number of studies, experienced world-class sites and investigators, and patient enrolment. Novotech, the largest biotech CRO in Asia Pacific, says the region has had a...

Phase 2 cystic fibrosis program for ELX-02 expected to be fully enrolled in the first quarter of 2020 and topline results expected during the first half of 2020 Positive Phase 2 topline data reported for ELX-02 in nephropathic cystinosis from the first treatment...

- Biologics Licensing Application (BLA) submission planned for late 2020 - SAN CARLOS, Calif., Jan. 15, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...

- Ongoing BUENA Trial to Continue at Increased Daily Dose - SAINT LAURENT, Quebec, Jan. 15, 2020 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that Health Canada has issued a No Objection...

Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it has...

Clinical trial using devimistat in combination with FOLFIRINOX as first-line treatment has enrolled more than 250 patients ahead of scheduled timeline Cranbury, NJ, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in...

Three-arm, three-month study will compare Viveve's cryogen-cooled monopolar radiofrequency (CMRF) treatment and cryogen-only sham to inert sham treatment ENGLEWOOD, CO / ACCESSWIRE / January 14, 2020 / Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company...

SEOUL, South Korea, Jan. 13, 2020 /PRNewswire/ -- Genome & Company (KONEX: 314130) is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to evaluate the safety,...